Perioral Dermatitis

Perioral (more accurately periorificial) dermatitis (POD) is a rash of small red, pink or skin-coloured bumps, sometimes with a few pustules and fine scale, clustered around the mouth, nose and eyes. The skin right next to the lip border is typically spared. Despite the name, it behaves more like rosacea than eczema (DermNet). In children it has been seen as young as 3 months, with an average age of 6.6 years and slightly more girls than boys. A granulomatous variant (CGPD), mainly reported in darker-skinned prepubertal children, gives firmer skin-coloured or brown papules and can involve the eyelids or body. Because toddlers with Atopic Dermatitis get facial redness anyway, POD is easily mistaken for an eczema flare and treated with more steroid, which makes it worse (Kellen & Silverberg, Cutis 2017).

Perioral Dermatitis [relates] Atopic Dermatitis Perioral Dermatitis [relates] Allergic Contact Dermatitis

Link to topical steroids on the face. Steroid exposure is the most consistent trigger. DermNet reports corticosteroid exposure in 58–72% of paediatric cases, and Goel et al.’s chart review of 222 children (3 months–18 years) found it in 58.1%. The exposure can be Topical Corticosteroids on the face, oral steroids, or inhaled and nasal steroids for asthma, where the spacer or mask leaves residue around the mouth. Weston and Morelli’s series of 106 children with “steroid rosacea” included 29 under 3 years, mostly exposed to low-potency (class 7) products. So even mild steroids can do it if used on the face for weeks. The mechanism is unclear: epidermal damage, changed follicle flora, and steroid suppression of inflammation all play a part. Steroids hide the rash while they are applied, and it rebounds when they stop. This is why the 2024 UK statement lists POD and steroid rosacea among conditions that can look like Topical Steroid Withdrawal, and why the MHRA tells prescribers to consider “peri-oral dermatitis” before stepping up potency when facial eczema does not settle. Children with atopic dermatitis are over-represented (29.3% in Goel et al.), probably because a weaker skin barrier lets irritants in more easily.

Topical Corticosteroids [causes] Perioral Dermatitis Perioral Dermatitis [relates] Topical Steroid Withdrawal Skin Barrier Dysfunction [relates] Perioral Dermatitis MHRA [relates] Perioral Dermatitis

Treatment. The first step everywhere is to stop the suspected cause: facial steroid, heavy or occlusive creams, and (where possible) inhaled-steroid residue. The inhaler or mask should be wiped and the indication reviewed with the asthma team. On its own this “zero therapy” clears many cases. Hall and Reichenberg’s evidence review (2010) found it among the best-supported options, and DermNet says the rash may flare briefly and then resolve within a few months. Mild cases are treated with a topical antibiotic: Metronidazole gel or cream, Erythromycin, clindamycin or sulfacetamide, usually clearing in 3–8 weeks. Topical Pimecrolimus reduces severity quickly, especially after prior steroid use, but does not shorten time to clearance. For widespread or stubborn disease in young children, oral erythromycin, azithromycin or clarithromycin is used for about 4–8 weeks. In Weston and Morelli’s regimen (oral erythromycin 30 mg/kg/day for 4 weeks after stopping the steroid), 86% of children cleared by 4 weeks and all by 8 weeks. Oral Tetracyclines (tetracycline, doxycycline, minocycline), the usual adult first line, are avoided in young children because they stain developing teeth. Average time to resolution in the Goel cohort was about 4 months.

Metronidazole [treats] Perioral Dermatitis Erythromycin [treats] Perioral Dermatitis Pimecrolimus [treats] Perioral Dermatitis Tetracyclines [treats] Perioral Dermatitis

Conflict: [Kellen & Silverberg, Cutis, Dec 2017] call topical metronidazole a pediatric “standard” (clearance in 3–8 weeks), and DermNet lists it first among topical options. [Hall & Reichenberg, G Ital Dermatol Venereol, Aug 2010] rate the evidence for topical metronidazole in children “relatively weak” (case series plus a trial showing it inferior to tetracycline). Unresolved — add to open_questions.

Conflict: Age cut-off for oral tetracyclines: [DermNet periorificial dermatitis, n.d.] makes erythromycin first-line for “children under 8 years”; [Kellen & Silverberg, Cutis, Dec 2017] say tetracyclines “must not be used in patients younger than 9 years”; [DermNet, POD in children, Dec 2018] says avoid them under 12. All agree they are unsuitable for 1–4-year-olds. Unresolved — add to open_questions.

Conflict: [Weston & Morelli, cited in Cutis 2017] stopped all topical steroids “immediately … without gradual withdrawal”; [another study cited in Cutis 2017] suggests low-potency TCS to control the rebound while weaning off stronger steroids; [DermNet, Dec 2018] warns rebound flares and steroid dependence prolong the course. Unresolved — add to open_questions.

Toddler safety and outlook. POD itself is harmless and usually self-limiting. In children it can settle within weeks once the trigger is removed, but recurrence is common in children dependent on corticosteroids (DermNet), and continued steroid use prolongs it. All the first-line treatments (stopping the steroid, topical metronidazole or erythromycin, oral macrolides) are routinely used in toddlers. The practical lesson for parents of 1–4-year-olds is to keep facial steroids to mild potency for short courses, as the Topical Corticosteroids note describes. A persistent bumpy rash around the mouth or nose that keeps coming back when the cream stops should be checked by a doctor, not treated with stronger steroid or labelled TSW at home. Low-potency steroids such as Hydrocortisone are not risk-free on the face. Most children in Weston & Morelli’s series had used class 7 (lowest-potency) products. Differential diagnoses a clinician will rule out include Impetigo (honey-coloured crusts), contact dermatitis, seborrhoeic dermatitis and fungal infection.

Hydrocortisone [relates] Perioral Dermatitis Impetigo [relates] Perioral Dermatitis Steroid Phobia [relates] Perioral Dermatitis

Do not "treat" a rash around the mouth with more steroid

A bumpy rash around a toddler’s mouth, nose or eyes that improves on steroid cream but flares every time it is stopped may be periorificial dermatitis. Stronger or longer steroid use makes it worse. See a GP or dermatologist for non-steroid treatment.

What parents report (evidence: anecdotal). No toddler-specific POD threads were collected in round 4. Online TSW communities often fold facial POD-type flares into TSW stories, which supports the UK statement’s point that POD is one of the treatable conditions mislabelled as TSW. The clinical message differs from TSW narratives: POD has a defined cause, standard non-steroid treatment, and a predictable recovery over weeks to months.

Connections

• Topical Steroid Withdrawal — recognised steroid side effect overlapping papulopustular TSW, source: NES/BDNG/BAD 2024
• Topical Corticosteroids — facial/inhaled/oral steroid exposure in 58–72% of paediatric cases, source: DermNet 2018
• Atopic Dermatitis — common background (29.3%) and frequent misdiagnosis, source: Cutis 2017
• Metronidazole — topical first-line in children, source: Cutis 2017; DermNet 2018
• Erythromycin — topical or oral macrolide for young children, source: DermNet; Cutis 2017
• Tetracyclines — adult first-line, avoided in young children, source: Cutis 2017; DermNet
• Pimecrolimus — reduces severity after steroid use, source: Hall & Reichenberg 2010
• MHRA — prescribers told to consider POD before escalating potency, source: MHRA DSU 2021
• Impetigo — differential diagnosis, source: Cutis 2017
• Drool Dermatitis — saliva irritant rash; steroids help it but worsen POD, source: Children’s Mercy 2024
• Lip-Licker’s Dermatitis — differential diagnosis, source: Children’s Mercy 2024
• Differential Diagnosis of Toddler Eczema — periorificial papulopustules mimic AD, source: Türe Avcı 2026